Stryker Co. (NYSE:SYK) VP Yin C. Becker sold 23,221 shares of the firm’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $165.96, for a total value of $3,853,757.16. Following the sale, the vice president now directly owns 10,499 shares of the company’s stock, valued at $1,742,414.04. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Stryker Co. (NYSE:SYK) opened at $166.38 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.29 and a quick ratio of 1.59. The stock has a market capitalization of $62,330.00, a PE ratio of 33.96, a PEG ratio of 2.41 and a beta of 0.70. Stryker Co. has a 52 week low of $129.82 and a 52 week high of $170.00.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.78 EPS. sell-side analysts expect that Stryker Co. will post 7.12 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on SYK. ValuEngine raised Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. Citigroup raised Stryker from a “sell” rating to a “neutral” rating and raised their price objective for the stock from $165.77 to $166.00 in a research report on Tuesday, February 27th. Morgan Stanley raised their target price on Stryker from $179.00 to $186.00 and gave the company an “overweight” rating in a report on Monday, February 26th. Oppenheimer restated a “hold” rating and set a $165.00 target price on shares of Stryker in a report on Thursday, February 1st. Finally, Guggenheim restated a “buy” rating on shares of Stryker in a report on Wednesday, January 31st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $163.85.
Several institutional investors and hedge funds have recently made changes to their positions in SYK. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Stryker in the 4th quarter valued at about $49,056,000. Elkfork Partners LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $49,005,000. Lazard Asset Management LLC boosted its stake in shares of Stryker by 15.5% in the 4th quarter. Lazard Asset Management LLC now owns 2,208,379 shares of the medical technology company’s stock valued at $341,945,000 after buying an additional 296,550 shares during the period. Ardevora Asset Management LLP purchased a new position in shares of Stryker in the 3rd quarter valued at about $34,568,000. Finally, William Blair Investment Management LLC purchased a new position in shares of Stryker in the 4th quarter valued at about $32,421,000. Institutional investors and hedge funds own 75.71% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://baseballnewssource.com/2018/03/15/stryker-co-syk-vp-sells-3853757-16-in-stock/2036419.html.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.